COMMUNIQUÉS West-GlobeNewswire

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
12/06/2024
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications
12/06/2024
NEW YORK, 12 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
12/06/2024
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transition Experienced life [...]
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
12/06/2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
NANOBIOTIX ORGANISE UNE DISCUSSION VIRTUELLE ENTRE EXPERTS SUR LE POTENTIEL DE NBTXR3 EN IMMUNOTHÉRAPIE DANS LE CANCER DE LA TÊTE ET DU COU ET D’AUTRES INDICATIONS LE 18 JUIN 2024
12/06/2024
PARIS et CAMBRIDGE, Mass., 12 juin 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
12/06/2024
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy [...]
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/06/2024
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of [...]
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12/06/2024
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and [...]
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
12/06/2024
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE [...]
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12/06/2024
The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an [...]
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
12/06/2024
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines [...]
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12/06/2024
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear sufficient for a [...]
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
12/06/2024
The cost of a rescheduled shareholder meeting could reach $100,000 NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that [...]
Clearday Supports National Health Observances
12/06/2024
San Antonio, TX, June 12, 2024 (GLOBE NEWSWIRE) -- Clearday (OTC- CLRD), supports the post on May 29, 2024, from the Office of Disease Prevention and Health Promotion. Said office features monthly National Health [...]
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
12/06/2024
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12/06/2024
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of the Company and the [...]
Tevogen Bio Set to Join Russell 3000® Index
12/06/2024
WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically [...]
Entourage Announces Results of 2024 Annual General Meeting of Shareholders
12/06/2024
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. ( TSX-V:ENTG ) ( OTCQX:ETRGF ) ( FSE:4WE ) (“ Entourage ” or the “ Company ”), a Canadian producer and distributor of award-winning cannabis products, is [...]
Sanofi: Information concerning the total number of voting rights and shares – May 2024
12/06/2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]

Pages